Flow cytometry stands as one of the most versatile single-cell analysis technologies in modern biomedical research, enabling simultaneous quantification of multiple surface and intracellular markers within heterogeneous populations at extraordinary throughput. Alfa Cytolog delivers tailored flow cytometry analysis services that integrate seamlessly with your preclinical tumor models, transforming raw cellular data into actionable pharmacodynamic insights.
Flow cytometry is a laser-based analytical technique that measures physical and chemical characteristics of cells or particles as they flow in a fluid stream through one or more lasers. In oncology research, it has become indispensable for dissecting tumor microenvironment composition, tracking immune cell infiltration, and evaluating therapeutic responses at the single-cell level. The technology captures scattered light and fluorescence emissions from labeled antibodies, allowing researchers to identify specific cell subsets based on marker expression, assess functional states such as proliferation or exhaustion, and quantify rare populations like circulating tumor cells.
Fig 1. The application of flow cytometry in the analysis of CAR T cells. (Shao, Lipei, et al., 2025)
The evolution of flow cytometry has progressed from early single-color systems to modern spectral platforms capable of resolving 17 or more parameters simultaneously. This expansion in dimensionality has transformed immunophenotyping from simple lineage identification into deep characterization of activation status, checkpoint expression, and cytokine production. In preclinical settings, flow cytometry bridges the gap between bulk tissue analysis and single-cell resolution, offering quantitative data that supports mechanism-of-action studies, biomarker discovery, and translational relevance of novel cancer therapeutics.
Spectral flow cytometry has emerged as a transformative advancement in high-parameter immunophenotyping, capturing the full emission spectrum of each fluorophore rather than relying on traditional optical filters. This technology enables laboratories to construct larger, more complex panels within a single assay while improving resolution of populations that previously overlapped in conventional systems. As clinical and preclinical demands shift toward deeper immune characterization—particularly in immuno-oncology trials and CAR-T therapy monitoring—spectral platforms are increasingly viewed as the next standard for comprehensive cellular analysis.
| Feature | Conventional Flow Cytometry | Spectral Flow Cytometry |
|---|---|---|
| Detection Principle | Bandpass optical filters | Full emission spectrum capture |
| Panel Capacity | 8–12 colors typical | 17+ colors in a single tube |
| Resolution | Limited by spectral overlap | Enhanced via spectral unmixing algorithms |
| Sample Requirement | Higher (multi-tube needed) | Lower (consolidated panels) |
| Primary Applications | Standard immunophenotyping | Deep profiling, rare subset detection |
| Data Complexity | Moderate | Higher, requires advanced software |
| Clinical Trajectory | Established diagnostics | MRD monitoring, transplant surveillance |
Alfa Cytolog operates a state-of-the-art flow cytometry platform designed specifically for preclinical oncology applications, combining conventional and spectral cytometry capabilities with deep expertise in tumor model endpoint analysis. Whether your program requires immune profiling of syngeneic models, CAR-T cell persistence tracking in humanized mice, or pharmacodynamic assessment of checkpoint inhibitors, our scientific team designs customized panels and gating strategies that align with your therapeutic hypothesis and deliver publication-ready data.
We characterize major immune subsets across blood, spleen, lymph nodes, and tumor infiltrates using validated multiparametric panels. Our services cover T-cell subpopulations (CD4+, CD8+, Tregs, exhausted T cells), myeloid-derived suppressor cells, tumor-associated macrophages, and dendritic cell subsets, enabling comprehensive mapping of the tumor immune microenvironment.
Our team quantifies therapeutic-induced cell death through Annexin V/PI staining, caspase activation assays, and mitochondrial membrane potential measurements. These assays distinguish early apoptotic cells from late apoptotic and necrotic populations, providing critical pharmacodynamic endpoints for cytotoxic and targeted agents.
Using DNA content analysis with propidium iodide and BrdU/EdU incorporation assays, we determine cell cycle phase distribution and proliferation rates in both in vitro cultures and ex vivo tumor samples. This supports mechanism-of-action studies for cell cycle inhibitors and antimitotic compounds.
We track adoptive cell therapy products in vivo through detection of transgene markers, proliferation markers (Ki-67), and exhaustion markers (PD-1, TIM-3, LAG-3). Our panels assess persistence, expansion kinetics, and functional status of therapeutic cells within the tumor microenvironment.
Our intracellular flow cytometry services quantify cytokine production (IFN-γ, TNF-α, IL-2, IL-6) and signaling pathway activation (phospho-proteins) at the single-cell level, revealing functional consequences of therapeutic intervention on specific immune subsets.
Each flow cytometry project at Alfa Cytolog follows a structured workflow designed to ensure data integrity, reproducibility, and scientific relevance. From initial consultation through final reporting, our process emphasizes rigorous panel validation, standardized staining protocols, and robust quality control measures tailored to your preclinical model system.
Our scientists collaborate with your team to define study objectives, select appropriate tissue sources, and design custom antibody panels optimized for your specific tumor model and therapeutic mechanism.
Tissue samples are dissociated into single-cell suspensions using enzymatic or mechanical methods. Viability dyes are applied to exclude dead cells and minimize nonspecific antibody binding.
Cells are incubated with fluorophore-conjugated antibodies targeting surface markers, followed by fixation, permeabilization, and intracellular staining when required for transcription factors or cytokine detection.
Samples are acquired on calibrated instruments with standardized PMT voltages. Internal controls, fluorescence-minus-one (FMO) controls, and compensation beads ensure accurate signal interpretation.
Our analysts apply rigorous gating strategies using FlowJo and advanced visualization tools including tSNE. Populations are quantified, and statistical comparisons are performed across treatment groups.
You receive comprehensive reports containing population frequencies, representative plots, statistical summaries, and raw data files in standard formats, accompanied by scientific interpretation and recommendations.
Flow cytometry serves as a cornerstone analytical platform across diverse preclinical oncology programs, delivering quantitative cellular insights that inform critical drug development decisions. Its versatility spans immune monitoring, pharmacodynamic assessment, and biomarker discovery in both solid tumor and hematologic malignancy models.
Ready to illuminate the cellular dynamics driving your therapeutic response? Reach out to our scientific team today to discuss how Alfa Cytolog's flow cytometry services can advance your preclinical oncology program. Contact us to schedule a consultation and receive a customized proposal tailored to your study design and endpoint requirements.
Reference
For research use only. Not intended for any clinical use.
Alfa Cytology, a provider of preclinical tumor model services, specializes in CDX, PDX, syngeneic, orthotopic, and humanized models. Supported by a broad portfolio of in vivo platforms and pharmacology expertise, we excel in oncology efficacy evaluation. We offer customized study designs tailored to diverse requirements – your demand is our mission.
Copyright © 2026 Alfa Cytology. All rights reserved.
